Verici Dx plc is an immuno-diagnostics developer primarily dedicated to innovations within the kidney transplantation field. It creates both prognostic (predictive) and diagnostic (identifying current conditions) assays specifically designed for kidney transplant recipients. Its developmental pipeline currently features several key tests: Clarava, a pre-transplant prognostic tool designed to assess the risk of early acute rejection. Tuteva, a post-transplant solution focused on identifying acute cellular rejection. Protega, a novel liquid biopsy that aims to predict the future risk of fibrosis and long-term graft failure. Established in 2020, the company operates from its base in Penarth, United Kingdom.
—
Verici Dx plc is an immuno-diagnostics developer primarily dedicated to innovations within the kidney transplantation field. It creates both prognostic (predictive) and diagnostic (identifying current conditions) assays specifically designed for kidney transplant recipients. Its developmental pipeline currently features several key tests: Clarava, a pre-transplant prognostic tool designed to assess the risk of early acute rejection. Tuteva, a post-transplant solution focused on identifying acute cellular rejection. Protega, a novel liquid biopsy that aims to predict the future risk of fibrosis and long-term graft failure. Established in 2020, the company operates from its base in Penarth, United Kingdom.
—
Daily adjusted close
Verici Dx plc is an immuno-diagnostics developer primarily dedicated to innovations within the kidney transplantation field. It creates both prognostic (predictive) and diagnostic (identifying current conditions) assays specifically designed for kidney transplant recipients. Its developmental pipeline currently features several key tests: Clarava, a pre-transplant prognostic tool designed to assess the risk of early acute rejection. Tuteva, a post-transplant solution focused on identifying acute cellular rejection. Protega, a novel liquid biopsy that aims to predict the future risk of fibrosis and long-term graft failure. Established in 2020, the company operates from its base in Penarth, United Kingdom.